The in vitro antimycotic activity and acute toxicity of third-generation bezylidenetetralones and heteroarylidenetetralones

Tahsin M. Al-Nakib, T. Lóránd, András Földesi, Ramani Varghese

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives: A new series of E-2-arylmethylene-1-tetralones and E-2-heteroarylmethylene-1-tetralones (third generation) were designed as potential antimycotic agents against human pathogenic yeasts. Methods: The new compounds were obtained by aldol condensation of 1-tetralone with the appropriately substituted aldehydes in either acid- or base-catalysed conditions. These compounds were tested for their in vitro antimycotic activity against 24 strains of Cryptococcus neoformans, Candida spp. and Trichosporon cutaneum by a microtitre well technique in a liquid casitone medium, using a double dilution method. The toxicity of the new compounds was determined in vitro in cultured HeLa cells, in HeLa growth medium and in vivo in MFI mice. Results: Nine-teen new E-2-benzylidine-1-tetralones were prepared, and 16 of the tested compounds showed superior antimycotic activity when compared to the first-generation E-2-benzylidine-1-tetralones synthesised previously. Twelve of these third-generation compounds were more active against different strains of yeasts than 6 commercial antimycotic agents similarly tested. An in vitro toxicity study and an in vivo acute toxicity study in MFI mice showed that these compounds were severalfold less toxic than most of the commerical antimycotics, with 4 being comparable to or less toxic than the least toxic of the commercial agents (amphotericin B) tested by the same procedures. Conclusions: Twelve members of this new E-2-benzylidine-1-tetralone class of compounds are promising candidates for antimycotic agents worthy of further investigation.

Original languageEnglish
Pages (from-to)191-196
Number of pages6
JournalMedical Principles and Practice
Volume10
Issue number4
DOIs
Publication statusPublished - 2001

Fingerprint

Tetralones
Poisons
Yeasts
Trichosporon
Cryptococcus neoformans
Amphotericin B
HeLa Cells
Candida
Aldehydes
In Vitro Techniques
Cultured Cells
Acids
Growth

Keywords

  • Acute toxicity
  • Antimycotic activity
  • Benzylidenetetralones
  • Heteroarylidenetetralones
  • In vitro
  • In vivo/in vitro

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The in vitro antimycotic activity and acute toxicity of third-generation bezylidenetetralones and heteroarylidenetetralones. / Al-Nakib, Tahsin M.; Lóránd, T.; Földesi, András; Varghese, Ramani.

In: Medical Principles and Practice, Vol. 10, No. 4, 2001, p. 191-196.

Research output: Contribution to journalArticle

@article{df348703e8cc4201a62f6329c624ba65,
title = "The in vitro antimycotic activity and acute toxicity of third-generation bezylidenetetralones and heteroarylidenetetralones",
abstract = "Objectives: A new series of E-2-arylmethylene-1-tetralones and E-2-heteroarylmethylene-1-tetralones (third generation) were designed as potential antimycotic agents against human pathogenic yeasts. Methods: The new compounds were obtained by aldol condensation of 1-tetralone with the appropriately substituted aldehydes in either acid- or base-catalysed conditions. These compounds were tested for their in vitro antimycotic activity against 24 strains of Cryptococcus neoformans, Candida spp. and Trichosporon cutaneum by a microtitre well technique in a liquid casitone medium, using a double dilution method. The toxicity of the new compounds was determined in vitro in cultured HeLa cells, in HeLa growth medium and in vivo in MFI mice. Results: Nine-teen new E-2-benzylidine-1-tetralones were prepared, and 16 of the tested compounds showed superior antimycotic activity when compared to the first-generation E-2-benzylidine-1-tetralones synthesised previously. Twelve of these third-generation compounds were more active against different strains of yeasts than 6 commercial antimycotic agents similarly tested. An in vitro toxicity study and an in vivo acute toxicity study in MFI mice showed that these compounds were severalfold less toxic than most of the commerical antimycotics, with 4 being comparable to or less toxic than the least toxic of the commercial agents (amphotericin B) tested by the same procedures. Conclusions: Twelve members of this new E-2-benzylidine-1-tetralone class of compounds are promising candidates for antimycotic agents worthy of further investigation.",
keywords = "Acute toxicity, Antimycotic activity, Benzylidenetetralones, Heteroarylidenetetralones, In vitro, In vivo/in vitro",
author = "Al-Nakib, {Tahsin M.} and T. L{\'o}r{\'a}nd and Andr{\'a}s F{\"o}ldesi and Ramani Varghese",
year = "2001",
doi = "10.1159/000050368",
language = "English",
volume = "10",
pages = "191--196",
journal = "Medical Principles and Practice",
issn = "1011-7571",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - The in vitro antimycotic activity and acute toxicity of third-generation bezylidenetetralones and heteroarylidenetetralones

AU - Al-Nakib, Tahsin M.

AU - Lóránd, T.

AU - Földesi, András

AU - Varghese, Ramani

PY - 2001

Y1 - 2001

N2 - Objectives: A new series of E-2-arylmethylene-1-tetralones and E-2-heteroarylmethylene-1-tetralones (third generation) were designed as potential antimycotic agents against human pathogenic yeasts. Methods: The new compounds were obtained by aldol condensation of 1-tetralone with the appropriately substituted aldehydes in either acid- or base-catalysed conditions. These compounds were tested for their in vitro antimycotic activity against 24 strains of Cryptococcus neoformans, Candida spp. and Trichosporon cutaneum by a microtitre well technique in a liquid casitone medium, using a double dilution method. The toxicity of the new compounds was determined in vitro in cultured HeLa cells, in HeLa growth medium and in vivo in MFI mice. Results: Nine-teen new E-2-benzylidine-1-tetralones were prepared, and 16 of the tested compounds showed superior antimycotic activity when compared to the first-generation E-2-benzylidine-1-tetralones synthesised previously. Twelve of these third-generation compounds were more active against different strains of yeasts than 6 commercial antimycotic agents similarly tested. An in vitro toxicity study and an in vivo acute toxicity study in MFI mice showed that these compounds were severalfold less toxic than most of the commerical antimycotics, with 4 being comparable to or less toxic than the least toxic of the commercial agents (amphotericin B) tested by the same procedures. Conclusions: Twelve members of this new E-2-benzylidine-1-tetralone class of compounds are promising candidates for antimycotic agents worthy of further investigation.

AB - Objectives: A new series of E-2-arylmethylene-1-tetralones and E-2-heteroarylmethylene-1-tetralones (third generation) were designed as potential antimycotic agents against human pathogenic yeasts. Methods: The new compounds were obtained by aldol condensation of 1-tetralone with the appropriately substituted aldehydes in either acid- or base-catalysed conditions. These compounds were tested for their in vitro antimycotic activity against 24 strains of Cryptococcus neoformans, Candida spp. and Trichosporon cutaneum by a microtitre well technique in a liquid casitone medium, using a double dilution method. The toxicity of the new compounds was determined in vitro in cultured HeLa cells, in HeLa growth medium and in vivo in MFI mice. Results: Nine-teen new E-2-benzylidine-1-tetralones were prepared, and 16 of the tested compounds showed superior antimycotic activity when compared to the first-generation E-2-benzylidine-1-tetralones synthesised previously. Twelve of these third-generation compounds were more active against different strains of yeasts than 6 commercial antimycotic agents similarly tested. An in vitro toxicity study and an in vivo acute toxicity study in MFI mice showed that these compounds were severalfold less toxic than most of the commerical antimycotics, with 4 being comparable to or less toxic than the least toxic of the commercial agents (amphotericin B) tested by the same procedures. Conclusions: Twelve members of this new E-2-benzylidine-1-tetralone class of compounds are promising candidates for antimycotic agents worthy of further investigation.

KW - Acute toxicity

KW - Antimycotic activity

KW - Benzylidenetetralones

KW - Heteroarylidenetetralones

KW - In vitro

KW - In vivo/in vitro

UR - http://www.scopus.com/inward/record.url?scp=0035682485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035682485&partnerID=8YFLogxK

U2 - 10.1159/000050368

DO - 10.1159/000050368

M3 - Article

AN - SCOPUS:0035682485

VL - 10

SP - 191

EP - 196

JO - Medical Principles and Practice

JF - Medical Principles and Practice

SN - 1011-7571

IS - 4

ER -